share_log

Transcode Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Fitzgerald Thomas A

SEC ·  Jun 19, 2024 04:22

Summary by Futu AI

Interim CEO and CFO of Transcode Therapeutics, Inc., Fitzgerald Thomas A, has engaged in a transaction involving the company's stock, as reported on June 14, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action reflects a change in the holdings of Fitzgerald Thomas A, which could be of interest to investors of Transcode Therapeutics, Inc. [RNAZ].
Interim CEO and CFO of Transcode Therapeutics, Inc., Fitzgerald Thomas A, has engaged in a transaction involving the company's stock, as reported on June 14, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action reflects a change in the holdings of Fitzgerald Thomas A, which could be of interest to investors of Transcode Therapeutics, Inc. [RNAZ].
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Related Stocks Related Stocks
    Symbol Mini Chart Price
    Conduit Pharmaceuticals
    CDT
    -- 0.123
    Unity Biotechnology
    UBX
    -- 1.7900
    Radiopharm Theranostics
    RADX
    -- 5.350
    DBV Technologies
    DBVT
    -- 4.970
    NRX Pharmaceuticals
    NRXP
    -- 4.8500

    Unlock the Full List